GlycoNex, Nippon Kayaku Partner to Advance Next-Gen ADC Candidate 

GlycoNex, Inc. (GNX), a clinical-stage biotechnology company focused on glycan-directed cancer immunotherapies, has entered into a collaboration agreement with Nippon Kayaku Co., Ltd. to advance GNX201-ADC, a next-gen antibody-drug conjugate (ADC) candidate for the treatment of solid tumors. The companies will jointly support preclinical development activities for GNX201-ADC, leveraging their respective expertise in antibody engineering and oncology drug development.

The collaboration will center on R&D activities for GNX201-ADC including optimization of the ADC construct and generation of preclinical data to support regulatory submissions. GNX201-ADC is designed as a protease-activated ADC that remains stable in circulation and is selectively activated in the tumor microenvironment, enabling targeted delivery of its cytotoxic payload while minimizing effects on normal tissues. This differentiated pro-antibody activation strategy is intended to improve therapeutic index and reduce on-target toxicity compared with conventional ADC approaches. Initial development efforts will focus on solid tumors characterized by high levels of glycan antigens.

GNX201-ADC leverages GlycoNex’s “Antibody Lock” technology, incorporating a protease-activated pro-ADC that is “turned on” when the masking peptide is removed in the tumor microenvironment and turned off with the masked domain when in circulation. This selective activation allows GNX201-ADC to target tumors without harming healthy tissue. The design aims to reduce the risk of on-target toxicity and associated adverse effects observed with conventional ADC approaches.